Cisplatin

erb-b2 receptor tyrosine kinase 2 ; Homo sapiens







149 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33538958 Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. 2021 Feb 4 1
2 33985511 Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. 2021 May 13 4
3 34211587 External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. 2021 1
4 34268956 Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer. 2021 May-Jun 2
5 34386088 Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer. 2021 Sep 4
6 34729945 HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. 2021 Dec 6
7 35070983 Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation. 2021 1
8 31790894 Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. 2020 Jan 1
9 32117718 Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway. 2020 1
10 32269724 Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. 2020 1
11 32494981 Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. 2020 Sep 1
12 32943881 Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report. 2020 1
13 33042632 Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. 2020 2
14 30088161 Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. 2019 Mar 1
15 30711995 Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. 2019 Feb 3
16 30799422 A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. 2019 2
17 30809308 Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. 2019 1
18 30856589 Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. 2019 Jun 1 2
19 30927036 Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. 2019 Jun 1
20 31102009 Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. 2019 Nov 1
21 31521263 Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. 2019 Dec 1 1
22 31772741 Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. 2019 Oct 1
23 32156946 [Two Cases of Complete Response to Trastuzumab Combined with Chemotherapy for Recurrence of HER2-Positive Gastric Cancer]. 2019 Dec 1
24 26780095 Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. 2018 2
25 28343375 FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. 2018 Jan 1
26 29090377 Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. 2018 Feb 1
27 29174919 Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. 2018 Apr 1
28 29290024 A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). 2018 Feb 2
29 29434871 Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. 2018 Feb 2
30 29451302 Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. 2018 Jul 15 2
31 30145203 Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. 2018 Nov 28 1
32 30692485 [A Case of Hepatic Resection after Neoadjuvant Chemotherapy for Single Liver Metastasis from Gastric Cancer with Positive Human Epidermal Growth Factor Receptor 2]. 2018 Dec 2
33 28160563 Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. 2017 Apr 4 1
34 28234911 Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. 2017 1
35 28260018 Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line. 2017 Apr 1
36 28526406 Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. 2017 Jul 8 1
37 28850174 Chemotherapy for advanced gastric cancer. 2017 Aug 29 2
38 28913549 Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. 2017 Nov 3
39 29108309 Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. 2017 Oct 3 1
40 26846307 Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. 2016 Feb 5 5
41 26893657 Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. 2016 Feb 1
42 27002325 A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. 2016 May 2
43 27284358 HER2-positive gastric cancer identified by serum HER2: A case report. 2016 Jun 1
44 27760940 [A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy]. 2016 Oct 2
45 25143433 Constitutively active ErbB2 regulates cisplatin-induced cell death in breast cancer cells via pro- and antiapoptotic mechanisms. 2015 Jan 1
46 25624920 Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. 2015 Feb 2
47 25661103 Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. 2015 Mar 1
48 25744576 Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. 2015 Apr 1
49 25812508 [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy]. 2015 Mar 3
50 26047983 Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. 2015 Oct 1